ReviewCureus2025
Cocaine- and Levamisole-Induced Vasculitis (CLIV).
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cocaine-Levamisole-Associated Vasculopathy Mimicking ANCA-Associated Vasculitis and Presenting With Pulmonary-Renal Syndrome Requiring VV-ECMO Support.The American journal of case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cocaine- and levamisole-induced vasculitis (CLIV) is a distinct form of drug-induced vasculitis characterized by dual antineutrophil cytoplasmic antibody (ANCA) positivity, rapidly progressive glomerulonephritis (RPGN), and diffuse alveolar hemorrhage (DAH). This systematic review synthesizes data from case reports, case series, and reviews published between 2015 and 2024 to clarify clinical presentations, diagnostic approaches, and management strategies. A comprehensive search of PubMed and Google Scholar using terms such as "levamisole-induced vasculitis," "cocaine-associated vasculitis," "dual ANCA vasculitis," "RPGN," and "DAH" identified 312 records. After removing 84 duplicates, 228 records were screened, 52 were assessed for eligibility, and 18 were included in the final analysis. Most patients presented with cutaneous, renal, and pulmonary involvement. Diagnostic tools included ANCA serology (MPO and PR3), biopsy, and imaging. Treatment most often involved corticosteroids, with severe cases requiring rituximab, cyclophosphamide, or plasmapheresis. Prognosis improved with early diagnosis and cessation of exposure. Recognition of CLIV in cocaine users presenting with ANCA-positive vasculitis is essential for early intervention and improved outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.